Form 4: Casdin Capital Reports Acquisition of 50,000 Shares in GeneDx Holdings Corp.

Casdin Capital, a significant shareholder in GeneDx Holdings Corp. (WGS), reported the acquisition of 50,000 shares of Class A Common Stock at a price of $23.3059 per share on May 13, 2024.

Summary

• On May 13, 2024, Casdin Capital, along with related entities and individuals, reported a transaction involving GeneDx Holdings Corp. (WGS) Class A Common Stock.
• Casdin Capital acquired 50,000 shares at a price of $23.3059 per share.
• Following the reported transaction, the total direct holdings of Class A Common Stock by Casdin Partners Master Fund, L.P. is 2,753,509 shares.
• Eli Casdin directly owns 3,142 shares.
• Casdin Partners FO1-MSV, LP directly owns 432,902 shares.
• CMLS Holdings LLC directly owns 333,144 shares.
• The reporting entities and individuals have disclaimed beneficial ownership of the reported securities except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing reporting a transaction. The acquisition of shares by a major shareholder could be seen as a positive signal, but without additional context, it's difficult to gauge the overall impact.

Positives

• The acquisition of additional shares by a major shareholder like Casdin Capital could be interpreted as a sign of confidence in the future prospects of GeneDx Holdings Corp.

Management Comments

• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of insiders and major shareholders. This filing indicates changes in ownership by a significant investor in the genetic testing sector.

Stakeholder Impact

• The acquisition of shares by Casdin Capital may have a slightly positive impact on shareholder confidence.

Key Dates